Latest news with #SciBase
Yahoo
4 days ago
- Business
- Yahoo
Bulletin from the annual general meeting in SciBase Holding AB (publ)
STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to convene the meeting (which is available on the Company's website ( The annual general meeting resolved: to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024; that no dividend shall be paid for the financial year 2024 and that the year's result shall be carried forward; to grant the board members and the CEO discharge from liability for the financial year 2024; that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor; that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 404,000 for the chairman of the board and SEK 135,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor is to be paid in accordance with approved invoices; for the period until the end of the next annual general meeting, to re-elect Jesper Høiland, Robert Molander and Diana Ferro as board members and to elect Anna Eriksrud as new board member, to re-elect Jesper Høiland as chairman of the board of directors and to elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for the Company, with Magnus Lagerberg as auditor incharge; to adopt principles for the appointment of a nomination committee; to implement an incentive program consisting of a directed issue of warrants and approval of transfer of warrants for the fulfillment of the Company's obligations under the incentive program; to amend the article of association to amend the limits of the Company's share capital and number of shares. Following the amendment, the share capital shall amount to at least SEK 16,914,781.65 and not more than SEK 67,659,126.60 and the number of shares shall be not less than 338,295,633 and not more than 1,353,182,532; and to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 30 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s). Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's website For additional information, please contact:Pia Renaudin, CEOPhone: +46 732 069 802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Phone: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: SciBase - Bulletin AGM 2025 (ENG) View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:
Business Insider
4 days ago
- Business
- Business Insider
Castle Biosciences enters collaboration, license agreement with SciBase
Castle Biosciences (CSTL) announced that it has entered into a collaboration and license agreement with SciBase utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis. Under the collaboration and license agreement, the companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of $5M when Castle sales reach $50M annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments.
Yahoo
4 days ago
- Health
- Yahoo
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB ('SciBase') utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD). 'We have been successful in developing several tests that enable clinicians to improve treatment plan decisions for their patients who have dermatological needs, and entering into this collaboration with SciBase extends our opportunity to bring additional solutions to these same dermatological clinicians,' said Derek Maetzold, chief executive officer of Castle Biosciences. 'In the projected field of use for AD flares specifically, there could be up to 24 million patients in the United States.1,2 The majority of patients who are on maintenance treatment unfortunately experience flares and therefore, have rescue treatment plans. The intent of this initial development program is to identify a test that can pre-symptomatically predict flares and, thus, enable patients to initiate rescue treatment plans to minimize or altogether avoid a flare. 'We are excited about the technology that SciBase has developed to date and the opportunity to leverage this technology to advance the care of patients with dermatological diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment – the majority of which are managed by the same dermatological clinician.' Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. 1 About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015, and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the opportunities, benefits and goals of the collaboration; the development of a successful diagnostic test that predicts flares in patients diagnosed with atopic dermatitis; Castle's ability to expand its offerings, address existing unmet needs and realize upstream opportunities; and Castle's growth initiatives. The words 'believe,' 'can' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: current dermatological clinicians may not have a desire to utilize additional offerings from Castle; subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Investor and Media Contact:Camilla Zuckeroczuckero@ Source: Castle Biosciences, while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients
STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch of the Nevisense Self-Pay Program in the US, a new initiative designed to improve patient access to the Nevisense test outside of traditional insurance coverage. The program is being implemented at dermatology practices enrolled in the self-pay solution and addresses increasing demand for the Nevisense test directly from patients and dermatologists. SciBase has enrolled several practices located throughout the US and plans to further expand the program to meet clinician and patient needs. Driven by evolving standards of care and a growing clinical emphasis on early detection, dermatologists have shown a strong interest in making Nevisense available to patients irrespective of payer status. The new Self-Pay Program empowers clinicians to incorporate Nevisense into their diagnostic workflow sooner - ensuring that patients at risk for melanoma are not left waiting due to insurance limitations. "We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection," said Pia Renaudin, CEO of SciBase. "The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care." As melanoma rates continue to rise globally, the importance of early diagnosis has never been greater. Nevisense offers a point-of-care solution that enhances clinical decision-making and supports earlier detection - ultimately improving outcomes and reducing the long-term burden on healthcare systems. With the introduction of the Self-Pay Program, SciBase is reinforcing its commitment to innovation, access, and sustainable healthcare. The initiative enables more patients to benefit from Nevisense while helping clinicians deliver exceptional care through early melanoma detection. For additional information, please contact:Pia Renaudin, CEO, tel. +46732069802, e-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@ About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: US cashpay v1 View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
